Skip to main content

Table 1 Descriptive characteristics at baseline of participants who completed the study (n =!3). Values are mean (standard deviation) unless otherwise indicated

From: Feasibility and safety of a 6-month exercise program to increase bone and muscle strength in children with juvenile idiopathic arthritis

Variable All participants (n = 13) Girls (n = 7) Boys (11 = 6)
Age (years) 13.0(2.0) 13.5 (2.3) 12.4(1.6)
Ethnicity (tt Asian/Caucasian/ Other) 3/8/2 1/5/1 2/3/ 1
Tanner stage (# 1/2/3/4/5) 3/3/4/2/1 1 /2/3/1/0 2/ 1/1/ 1/1
Maturity offset (years) 0.07(1.8) 1.0 (1.9) −1.0 (1.0)
Height (cm) 149.7(8.3) 150.0(9.6) 149.4 (7.4)
Height z-score −0.61 (0.83) −0.80(0.%) −0.39 (0.66)
Weight (kg) 42.6(7.0) 41.1 (43.9) 41.1 (5.0)
Weight z-score −0.39 (1.26) −0.48(1.21) − 0.28 (1.42)
BMI (kg/m2) 18.8(2.6) 19.4 (2.2) 18.5(3.1)
BMI z-score −0.07 (1.26) 0.02(0.87) −0.19 (1.69)
Clinical outcomes
Time since diagnosis (months) 57 (47) 78 (23) 34 (49)
JIA subtvpes - polyarticular course 4 (2 poly RF negative, 2 oligo extended) 3 (2 poly RF negative, 1 oligo extended) 1 (oligo extended)
JIA subtypes - oligoarticular course 9 (2 oligo persistent. 3 ERA. 2 psoriatic, 2 undi fterentiated) 4 (2 psoriatic, 1 oligo persistent, 1 undifferentiated) 5 (3 ERA, 1 oligo persistent, 1 undifferentiated)
Medications (n) 7 NSAIDS,9 DMARDs, 4 Biologies 5 NSAIDS, 6 DMARDs, 3 biologies 2 NSAIDS, 3 DMARDs, 1 biologic
Fracture history 4 1 distal radius, 1 nasal 1 distal radius, 1 distal tibia
Dietary calcium intake (mg) 740 (410) 468 (196) 1058 (364)
  1. NSAIDs non-steroidal anti-inflammatory medications including Naproxen. Ibuprofen. DMARDs, Disease modifying anti-rheumatic drugs including Methotrexate, Leflunomide, Sulfasalazine. Biologies - including Etanercept. Infliximab, Humira